OptiBiotix 2025 trading update: growth, fatter margins, and a pivot to profit
OptiBiotix Health has kicked off 2026 with momentum after a stronger 2025. Unaudited figures show revenue up 30% to £1.13 million, gross profit up 82% to £603,000, and gross margins stepping up to 53% from 38%. Sales orders rose 33% to £1.34 million, including £212,000 carried forward for delivery in 2026.
Costs were kept in check, with operating costs stable at £2.6 million. Cash increased to £1.03 million, and the Group ended the year holding stakes in ProBiotix Health and SkinBioTherapeutics worth £6.45 million as at 31 December 2025. The tone from management is clear: the investment phase is largely complete, and the focus now is on commercial sustainability.
Key numbers at a glance
| Metric (unaudited) | 2025 | 2024 | Change |
|---|---|---|---|
| Sales orders | £1.34m | n/d | +33% (incl. £212k carried to 2026) |
| Revenue | £1.13m | £870k | +30% |
| Gross profit | £603k | £331k | +82% |
| Gross margin | 53% | 38% | +15 pp |
| Operating costs | £2.6m | £2.6m | Stable |
| Cash balance | £1.03m | £739k | Higher |
| PBX + SBTX holdings (market value) | £6.45m | n/d | As at 31 Dec 2025 |
Why this matters: quality of growth and operating leverage
The step-up in gross margin to 53% is the standout. It suggests a healthier product mix and better pricing or cost control, which is vital for a company scaling from a small base. Gross profit of £603,000 is still below operating costs of £2.6 million, so profitability has not been reached yet, but the direction of travel improves the operating leverage story as volumes build.
Management says the heavy lifting on IP, clinical support for claims, and building manufacturing, distribution and ecommerce infrastructure is largely done. If true, more of each incremental pound of revenue should flow through to profit as cost-saving actions bite.
Commercial traction: Hydroxycut, Asia launches, and a new channel
The product story is broadening. SlimBiome is now in Hydroxycut, which markets itself as the No. 1 selling weight loss supplement brand in the USA – that is a meaningful validation point for a microbiome-focused ingredient. There is also a signed distribution agreement with a well-known direct selling weight management company, with a first order received in H2 2025 and product launch slated for H1 2026.
In Asia, momentum is building with 17 products launched and 74 customer projects at various stages across six countries. This is the kind of pipeline that can turn into multi-year revenue if even a fraction convert into steady reorders.
2026 starts strong: Taiwan bulk order and record order book
Post period, Meelung Trading in Taiwan placed a 24 metric tonne SlimBiome order to be delivered roughly quarterly across 2026, with payment already received for the first 6mt. That brings visibility on volumes and cash collection – both helpful for planning and margins.
January 2026 also saw over £800,000 of orders for delivery during 2026, including the carried-forward orders. Importantly, this excludes ecommerce and subsequent orders. Taken together, that is a record start that backs up management’s confidence.
Pivot to commercial sustainability: deep cost cuts and margin gains
OptiBiotix is tightening the belt and sharpening margins. Actions already in train include:
- Marketing and selling costs cut by 78% in January and February 2026, with further reductions in R&D and IP expected. Anticipated annual savings: £500,000-£600,000.
- Cost of goods improvements expected to reduce SlimBiome production costs by 31% on Q2 2026 orders, with further changes targeted to reach a 48% reduction. That should lift gross margin and gross profit.
- Profit and loss accounts for each business unit (OptiBiotix Health USA, OptiBiotix Health India, Ecommerce and B2B), each tasked with covering their costs by end of 2026.
These are tangible levers. The caveat is execution: maintaining growth while cutting spend is a fine balance. But if the order book holds up, the maths should improve quickly.
Second-generation products: SweetBiotix production breakthrough
On the innovation front, an optimised enzyme-based production process for SweetBiotix now delivers higher yields, a purer and better-tasting product, and lower ingredient and production costs. That combination can widen margins and improve commercial appeal when second-generation products scale.
The Board highlights accelerating commercialisation of these second-generation products alongside the first-generation range. If SweetBiotix moves from tech to traction, it could diversify revenue and reduce reliance on any single channel or territory.
Balance sheet, investments, and market exposure
Cash at £1.03 million provides a modest buffer, and the listed holdings in ProBiotix Health and SkinBioTherapeutics were valued at £6.45 million at year-end. The Company notes that recent announcements by SkinBioTherapeutics have impacted the current value of that holding, though it believes SBTX’s fundamentals are strong. Market-valued assets can help optics, but they can also swing – something to keep in mind.
My view: encouraging progress, now down to delivery
Positives:
- Revenue growth of 30% with gross margin up to 53% – that is quality progress, not just top-line inflation.
- Record order intake into early 2026 and a chunky 24mt SlimBiome order with cash already in for the first tranche.
- Major brand validation via Hydroxycut, widening Asian footprint, and a new direct selling route to market.
- Concrete cost and margin actions that, on paper, materially improve the path to profitability.
Watch-outs:
- Gross profit still trails operating costs; profitability is an ambition, not a reality yet.
- Aggressive cost cuts need to be managed so they do not dent growth momentum.
- Exposure to partner execution and timing, particularly for the new channel launching in H1 2026.
- Valuation of listed holdings can move around with the market and company newsflow.
Overall, this is one of OptiBiotix’s more confident updates: better margins, meaningful orders, and specific cost-out targets. If the 31%-48% cost reduction on SlimBiome flows through as guided and the pipeline converts, 2026 could be a step-change year for the P&L.
What to watch next in 2026
- Delivery cadence of the 24mt Taiwan order and reorders thereafter.
- H1 2026 launch performance with the direct selling weight management partner.
- Q2 2026 orders reflecting the 31% cost reduction in SlimBiome and any update towards the 48% target.
- Conversion of the 74 Asia projects and traction of the 17 launched products.
- Progress on SweetBiotix commercial deals following the improved production process.
- Evidence that each business unit is moving towards cost coverage by year-end.
Dig deeper or ask management
You can subscribe for updates and engage with the team via OptiBiotix’s site: optibiotix.com/auth/signup. The full announcement and Q&A portal are here: optibiotix.com/link/rDGmLe. Company site: www.optibiotix.com.
